Compare Adaptive Biotechnologies Corp (ADPT) vs SYSCO Corporation (SYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs SYSCO Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while SYSCO Corporation trades at $83.25 (market cap $40.46B). The key difference: SYSCO Corporation is far larger — about 12.2× Adaptive Biotechnologies Corp's market cap, and SYSCO Corporation pays a 2.6% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SYY | |
|---|---|---|
Market Cap | $3.33B | $40.46B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $91.16 |
52-Week Low | $10.24 | $69.30 |
Enterprise Value | $3.19B | $53.94B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Sysco (SYY) trades at $84.62, down 0.25% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains steady revenue growth, reaching $81.37B in 2025. Analyst consensus is a Buy with a $83.67 price target, supported by recent corporate developments including AI awards and World Cup supply chain preparations.
Outlook remains positive due to strong institutional support and strategic initiatives, though risks include margin pressure from rising costs and high debt levels. The stock's valuation metrics like P/E of 23.4 and P/S of 0.49 suggest reasonable pricing, but investors should monitor execution on future earnings and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
